A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Recruiting · 40 sites across 23 states
Always free
Study care at no cost to you
For your time and travel
Many studies pay you back
Most need no insurance or papers
Legal status usually isn't required; we'll tell you each study's requirements
Interpreters available
Ask for your language
Your choice
Voluntary — you can stop anytime
What is this study?
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers.
It is , overseen by an independent and licensed medical staff.
Read the full clinical description
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.
Who this study is looking for
In plain language, from the study's own rules. The study team confirms the full details with you — this isn't a final yes or no.
✅ You may be able to join if…
- •Adults age 18 to 75.
- •Have type 2 diabetes for at least 6 months.
- •HbA1c between 7.0% and 10.5% (a blood test that shows average sugar over time).
- •BMI between 23 and 50 kg/m².
- •Are on a stable dose of metformin (at least 1000 mg/day) for at least 3 months (with or without an SGLT2 inhibitor).
🚫 You may not be able to join if…
- •Have type 1 diabetes or a history of diabetic ketoacidosis (a serious sugar emergency).
- •Use insulin to control blood sugar within the past 12 months.
- •Have used a GLP-1 receptor agonist within the past 6 months, or have used CX11 before.
- •Had certain heart/blood vessel problems within the past 6 months (for example, heart attack, stroke/TIA, unstable angina, or certain heart rhythm or ECG safety problems).
- •Have certain stomach, pancreas/gallbladder, thyroid, liver, eye, cancer, or kidney/lab problems at screening (including eGFR < 60 mL/min/1.73 m²).
Are you a good fit?
Simplified highlights. The study team always confirms the full details with you.
- ✓Adults roughly 18–75
- ✓A BMI around 23 or higher
- ✓Have Obesity / overweight or Type 2 diabetes
- !Some conditions may not be a fit: Fatty liver disease (NASH/MASH), Heart / cardiovascular disease, High blood pressure, Kidney disease
- !May require a break from current GLP-1 medications
What to expect, step by step
- 1
Usually a few weeks
The study team checks whether the study is a good fit for you, with a visit and sometimes lab tests. You can ask any questions before deciding.
- 2
Treatment
If you join and choose to continue, you receive the study treatment and are watched closely by medical staff.
- 3
Follow-up
After treatment, the team checks on your health and confirms the visit schedule with you. You can leave the study at any point.
Has this treatment been tested before?
Yes. This treatment has already been through earlier human studies for safety before reaching this stage.
What you need to know before you apply
What is this study testing?+
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers.
Is it safe? Who makes sure of that?+
This is a mid-stage study (Phase 2), looking at safety and whether the treatment works. Every study is reviewed and monitored by an independent ethics board (called an IRB) whose job is to protect participants, and care is overseen by licensed medical staff. You'll be told the known risks before you agree to anything, and you can stop at any time.
Will I get a placebo instead of the real treatment?+
Some studies compare a treatment against a placebo (an inactive version), and some don't. If this one does, the study team will explain your chances of receiving the active treatment before you decide. Nothing is hidden from you.
I take a GLP-1 medication (like Ozempic or Wegovy). Can I still join?+
Maybe. This study may ask you to pause certain weight or diabetes medications for a period of time (a 'washout') before joining, or it may be looking for people not currently on them. The coordinator will review your medications with you — don't stop any medication on your own.
Does it cost anything? Will I be paid?+
The study treatment and study-related visits are provided at no cost to you. This study may also compensate you for your time and travel — the team will tell you the amount before you join. You should never be asked to pay to take part.
Do I need insurance? Will anyone ask about my immigration status?+
No. You do not need health insurance to take part in a research study, and you will not be asked about your immigration status to join. Taking part is about whether you're a medical fit for the study.
What if English isn't my first language?+
You have the right to understand everything before you agree. Study sites can often provide materials or an interpreter in your language — you can ask the coordinator for one.
Is my information private?+
Yes. Your health information is only shared with the study sites you choose to be contacted by, and only to help match and enroll you. It is never sold, and you can ask us to delete it at any time.
Some requirements (like specific lab values or timing) are confirmed directly by the study team, not by us.
Source: ClinicalTrials.gov · NCT07340320 · Locations: Alabama · California · Florida · Georgia · Illinois · Indiana · Maryland · Massachusetts · Michigan · Minnesota · New Jersey · New Mexico · North Carolina · Oklahoma · South Carolina · Texas · Virginia · Greater Poland Voivodeship · Kuyavian-Pomeranian Voivodeship · Lesser Poland Voivodeship · Lower Silesian Voivodeship · Lódzkie · Masovian Voivodeship